Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $VSTM
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/24/2025 | $7.00 → $10.00 | Buy | H.C. Wainwright |
12/31/2024 | $13.00 → $20.00 | Buy | BTIG Research |
9/30/2024 | $13.00 | Buy | Guggenheim |
11/21/2023 | $27.00 | Buy | BTIG Research |
9/27/2023 | $21.00 | Buy | B. Riley Securities |
6/15/2023 | $24.00 → $36.00 | Neutral → Buy | Mizuho |
9/7/2022 | $6.00 | Buy | Alliance Global Partners |
4/29/2022 | $6.00 → $5.00 | Overweight | Cantor Fitzgerald |
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor more potent than other KRAS G12D inhibitors in preclinical models VS-7375, when combined with cetuximab, demonstrated strong tumor regressions in preclinical KRAS G12D models, including complete responses in a colorectal cancer model In a patient-derived LGSOC xenograft model, an FAK inhibitor addition to avutometinib augmented tumor regression with stronger inhibition of MAPK, PI3K and YAP/TEAD signaling than either agent alone The combination of avutometinib, a RAF/MEK clamp, with a pan-RAF inhibitor led to strong tumor regressions in multiple NRAS- and BRAF-driven tumor models corresponding with nearly complete shutd
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data projects a 20% rise in annual cases by 2030 and a staggering 75% increase by 2050. According to the World Health Organization (WHO), breast cancer cases are projected to rise by nearly 40% by 2050. Despite the concerning trends in cancer incidence, 2025 has seen key advancements from biotech companies at the forefront of oncology research, with Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Exelixis, Inc. (NASDAQ:EXEL), Cardiff Oncology, Inc. (NASDAQ:CRDF
H.C. Wainwright reiterated coverage on Verastem with a new price target
H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously
BTIG Research reiterated coverage on Verastem with a new price target
BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously
Guggenheim initiated coverage on Verastem with a new price target
Guggenheim initiated coverage of Verastem with a rating of Buy and set a new price target of $13.00
Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)
4 - Verastem, Inc. (0001526119) (Issuer)
Chief Financial Officer Calkins Daniel sold $631 worth of shares (91 units at $6.93), decreasing direct ownership by 0.11% to 86,348 units (SEC Form 4)
4 - Verastem, Inc. (0001526119) (Issuer)
President and CEO Paterson Dan sold $1,696 worth of shares (244 units at $6.95), decreasing direct ownership by 0.07% to 346,479 units (SEC Form 4)
4 - Verastem, Inc. (0001526119) (Issuer)
Director Gagnon Robert E. sold $1,974 worth of shares (284 units at $6.95), decreasing direct ownership by 0.82% to 34,193 units (SEC Form 4)
4 - Verastem, Inc. (0001526119) (Issuer)
SEC Form EFFECT filed by Verastem Inc.
EFFECT - Verastem, Inc. (0001526119) (Filer)
SEC Form 424B3 filed by Verastem Inc.
424B3 - Verastem, Inc. (0001526119) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.
SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)
Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th
Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population The Company recently met with the FDA to review the mature data set and remains on track to complete the NDA submission in October 2024 Additional data to be presented at the IGCS meeting and during Company-hosted investor conference call and webcast today, October 17, 2024 at 4:30 pm EDT Verastem Oncology (NASDAQ:VST
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting
Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The late-breaking abstract is embargoed until the morning of the presentation at IGCS. The oral presentation will include updated safety and
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024 Plan to present the mature dataset from RAMP 201 at a medical conference in the second half of 2024 Avutometinib and defactinib combination have continued to show robust and durable response rates in ongoing RAMP 201 trial in patients with recurrent low-grade serous ovarian cancer Company to host investor conference call and webcast on Friday, May 24, 2024 at 8:00 am EDT to provide update on RAMP 201 and rolling NDA submission Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with canc
Amendment: SEC Form SC 13G/A filed by Verastem Inc.
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
Amendment: SEC Form SC 13G/A filed by Verastem Inc.
SC 13G/A - Verastem, Inc. (0001526119) (Subject)
SEC Form SC 13G filed by Verastem Inc.
SC 13G - Verastem, Inc. (0001526119) (Subject)